Quality of life in ovarian cancer patients receiving chemotherapy—preliminary study

Objective: Evaluate quality of life in ovarian cancer patients. Methods: To collect information, a diagnostic survey was carried out using the standardised survey questionnaires QLQ-C30 (quality of life questionnaire) and QLQ-OV28. The 105 women who were enrolled in the study had been diagnosed at the Diagnostic Imaging Centre and were undergoing treatment at the Chemotherapy Department of the Provincial Polyclinical Hospital in Toruń. Results: The study group consisted of women aged 35–72 years. The average age of the women was 53.2 years. Most women had secondary education—46.7%, the fewest group had vocational education—13.3%. On a scale of 1–7, most of the women rated their health status from the previous week at 4 points—31.4%, at 5 points—27.6%, and at 3 points—22.9%. Similar results were found for quality of life: 4 points—32.4%, 5 points—25.7%, and 3 points—21.9%. The women aged 45 years and younger gave the highest rating to all the sub-scales, apart from hormonal symptoms (80.45 s ±12.96) and body image (61.60 s ± 28.63), which received the highest rating from the women aged >62 years. Conclusion: The quality of life in ovarian cancer patients is related to their age, education and marital status. There is a correlation between the quality of life of the respondents and their family history of ovarian and/or breast cancer.

Quality of life; Ovarian cancer; Questionnaire QLQ-C30; QLQ-OV28

[1] Stelmach-Mardas M, Kubisz L, Mojzykiewicz M, Mardas M. Dietary habits and ovarian cancer. Forum Zaburzeń Metabolicznych. 2018; 2: 81–85.

[2] K Plagens-Rotman, M Piskorz–Szymendera, B Pięta. Lifestyle with particular emphasis on physical activity and genital carcinomas in women. European Journal of Gynaecological Oncology. 2020; 2: 233–239.

[3] Plagens-Rotman K, Chmaj-Wierzchowska K, Pięta B, Bojar I. Modifiable lifestyle factors and ovarian cancer incidence in women. Annals of Agricultural and Environmental Medicine. 2018; 25: 36–40.

[4] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival efect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology. 2002; 20: 1248–1259.

[5] Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecologic Oncology. 2006; 103: 559–564.

[6] Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology. 2008; 108: 276–281.

[7] Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007; 25: 3621–3627.

[8] The National Comprehensive Cancer Network, Inc. 2017 NCCN, NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer, version 1. 2016. Journal of the National Comprehensive Cancer Network. 2016; 14: 1134–1163.

[9] Chmaj-Wierzchowska K, Wojciechowska M, Parda I, Plagens- Rotman K, Rzymski P, Wilczak M. How do health problems af- fect the quality and everyday life of patients with endometriomas? Clinical and Experimental Obstetrics and Gynecology. 2020; 4: 571–575.

[10] Połocka-Molińska M, Jurczyk M. Quality of life of women with inoperable ovarian cancer. Current Gynecologic Oncology. 2011; 9: 82–94.

[11] Majdak E, Mielcarek P, Kozaka J, Krasińska L, Kobierski J, Emerich J. Age-related differences in the quality of life in advanced ovarian cancer patients treated with first-line intravenous chemotherapy. Psychoonkologia. 2002; 6: 31–35.

[12] Miniszewska J, Chrystowska-Jabłońska B. Strategies of coping with cancer disease and quality of life. Psychoonkologia. 2002; 6: 89–94.

[13] Vaz AF, Conde DM, Costa-Paiva L, Morais SS, Esteves SB, PintoNeto AM. Quality of life and adverse events after radiotherapy in gynecologic cancer survivors: a cohort study. Archives of Gynecology and Obstetrics. 2011; 284: 1523–1531.

[14] Kotlińska-Lemieszek A. Pain in a patient with cancer can be re- lieved effectively in the majority of cases, but not always. Why do we encounter difficulties? Medicina Paliativa. 2009; 1: 11–21.

[15] Leppert W., Forycka M. Pain and quality of life assessment in cancer patients. Gastroenterologia Polska. 2011; 18: 127–131.

[16] Biskup A, Plagens-Rotman K, Polocka-Molinska M, Merks P. The impact of multimodal therapies on the comfort and safety of patients in the immediate post-anaesthetic period following gynaecological procedures - part I. Ginekologia Polska. 2021; 92: 85–91.

[17] Mangone L, Mandato VD, Gandolfi R, Tromellini C, Abrate M. The impact of epithelial ovarian cancer diagnosis on women’s life: a qualitative study. European Journal of Gynaecological Oncology. 2014; 35: 32–38.

[18] Plagens-Rotman K, Jarząbek-Bielecka G, Merks P, Mizgier M, Kędzia W, Wilczak M. Disability vs the sexual life of women - selected issues. Clinical and Experimental Obstetrics & Gynecology. 2021; 48: 19–23.

[19] Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, et al. Recommended patient-reported core set of symp- toms and quality-of-life domains to measure in ovarian cancer treatment trials. Journal of the National Cancer Institute. 2014; 106: dju128.

[20] Blumenfeld Z. Comment on: sexual and fertility adverse effects associated with chemotherapy treatment in women. Expert Opinion on Drug Safety. 2014; 13: 1283–1285.

[21] Turan V, Oktay K. Sexual and fertility adverse effects associated with chemotherapy treatment in women. Expert Opinion on Drug Safety. 2014; 13: 775–783.

[22] Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psycho-Oncology. 2013; 22: 2408–2418.

[23] Shankar A, Prasad N, Roy S, Chakraborty A, Biswas AS, Patil J, et al. Sexual Dysfunction in Females after Cancer Treatment: an Unresolved Issue. Asian Pacific Journal of Cancer Prevention. 2017; 18: 1177–1182.

[24] La Rosa VL, De Franciscis P, Barra F, Schiattarella A, Tropea A, Tesarik J, et al. Sexuality in women with endometriosis: a critical narrative review. Minerva Medica. 2020; 111: 79–89.

[25] Audette C, Waterman J. The sexual health of women after gynecologic malignancy. Journal of Midwifery & Women’s Health. 2010; 55: 357–362.

[26] Mütsch J, Friedrich M, Leuteritz K, Sender A, Geue K, Hilbert A, et al. Sexuality and cancer in adolescents and young adults - a comparison between reproductive cancer patients and patients with non-reproductive cancer. BMC Cancer. 2019; 19: 828.

[27] Geue K, Schmidt R, Sender A, Sauter S, Friedrich M. Sexuality and romantic relationships in young adult cancer survivors: sat- isfaction and supportive care needs. Psycho-Oncology. 2015; 24: 1368–1376.

[28] Algarroba GN, Sanfilippo JS, Valli-Pulaski H. Female fertility preservation in the pediatric and adolescent cancer patient population. Best Practice & Research. Clinical Obstetrics & Gynaecology. 2018; 48: 147–157.

[29] Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine. 2016; 14: 1.

[30] Peccatori FA, Azim HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24: vi160–vi170.

[31] Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. “What Doesn’t Kill you Makes you Stronger”: an Ovarian Cancer Survivor Survey. Gynecologic Oncology. 2001; 83: 537–542.

[32] Harter P, Schrof I, Karl LM, Hils R, Kullmann V, Traut A, et al. Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer. Geburtshilfe Und Frauenheilkunde. 2013; 73: 428–432.

[33] Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Supportive Care in Cancer. 2005; 13: 219–227.